Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06071767 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06071767 · ClinicalTrials.gov record · last posted 2026-08-26

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

StatusSuspended
PhasePhase 1/2
Started2024-04-01
View on ClinicalTrials.gov ↗
Why the trial stopped
Temporarily Closed (Paused) to Accrual and Study Agents/Products
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

Protocol amendment history 2 changes detected by DataLookout

2026-08-27
Recruitment suspended
2026-08-27
Recruitment suspended: Temporarily Closed (Paused) to Accrual and Study Agents/Products
Trial Details
NCT Number NCT06071767
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: University of Oxford, Gilead Sciences
Conditions HIV-1-infection
Enrollment 36 participants
Start Date 2024-04-01
Primary Completion 2028-04-29 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-26